Mechanism Differences: GLP-1 vs Dual Receptor Action
Compare Wegovy and Mounjaro: Understanding Different Mechanisms
When you compare Wegovy and Mounjaro, the fundamental difference lies in their receptor targeting mechanisms. Wegovy contains semaglutide, a GLP-1 receptor agonist that mimics the natural fullness hormone GLP-1, working specifically on appetite centres in your brain to promote satiety and reduce food cravings. Mounjaro, containing tirzepatide, operates as a dual agonist targeting both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 receptors simultaneously. This dual action potentially affects both appetite regulation and glucose metabolism through different pathways. Both treatments require prescription-only medicine status and must be used alongside a reduced-calorie diet and increased physical activity. Understanding these mechanism differences helps explain why some patients may respond differently to each treatment option.
The choice between these mechanisms often depends on individual patient factors and medical history. Your prescriber will evaluate which receptor targeting approach aligns best with your specific weight management goals and any existing health conditions. Both Wegovy and Mounjaro are available from EverydayMeds, allowing your healthcare provider to select the most appropriate option without supply limitations affecting their clinical decision-making process.
Wegovy vs Mounjaro Pricing: Complete UK Cost Comparison
To effectively compare Wegovy and Mounjaro pricing, understanding the complete cost structure for each treatment helps inform your decision. Wegovy pricing starts with the 0.25mg starter dose at £79.99, progressing through 0.5mg (£94.99), 1mg (£99.99), 1.7mg (£139.99), to the 2.4mg maintenance dose at £209.99. New customers can apply discount code FIRST40 at checkout, whilst returning customers use code DOSE25. EverydayMeds offers convenient bundle options including the Intro Duo (0.25mg & 0.5mg) for £169.99 and the Ultimate Stability Trio (three 2.4mg pens) providing three months of maintenance supply for £649.99. All pricing includes next-day cold-chain delivery and prescriber review through our GPhC-registered pharmacy (#9012878).
Mounjaro follows a different pricing structure with six dose levels from 2.5mg to 15mg, reflecting its distinct dose escalation schedule compared to Wegovy's five-dose progression. When comparing total treatment costs, consider that both medications require long-term commitment for sustained weight management benefits, as clinical evidence suggests patients may regain approximately two-thirds of weight lost within one year of stopping treatment. Bundle options provide convenience through Reliable Supply continuity and fewer individual orders, though the primary value lies in treatment consistency rather than cost savings.
Clinical Evidence When You Compare Wegovy and Mounjaro
Clinical evidence for both treatments comes from separate trial programmes with different designs, populations, and endpoints, making direct efficacy comparisons inappropriate. Wegovy's evidence base includes the STEP trial series, with STEP 1 showing patients achieved approximately 15% average weight loss at 68 weeks compared to 2.4% with placebo, when used alongside diet and exercise modifications as referenced in Wilding et al., NEJM, 2021. The SELECT cardiovascular outcomes trial demonstrated a 20% reduction in major cardiovascular events (HR 0.80) in patients with established cardiovascular disease. Additional STEP trials showed sustained results at two years and benefits in patients with type 2 diabetes.
Mounjaro's clinical evidence derives from the SURMOUNT trial programme, evaluating tirzepatide specifically for weight management in various patient populations. Both evidence bases support their respective MHRA approvals for weight management in adults with BMI ≥30, or BMI ≥27 with weight-related comorbidities. Rather than comparing percentage outcomes directly, focus on which treatment mechanism and dosing approach aligns better with your individual circumstances and medical profile.
How Wegovy Works in Wegovy vs Mounjaro Comparison
Understanding how Wegovy works provides crucial context when comparing Wegovy and Mounjaro options for weight management. Wegovy's active ingredient, semaglutide, functions as a GLP-1 receptor agonist, closely mimicking the natural hormone GLP-1 that your body produces in response to food intake. This mechanism targets specific receptors in your brain's appetite control centres, promoting feelings of fullness after smaller meals and potentially reducing cravings for high-calorie foods. The once-weekly injection delivers consistent therapeutic levels throughout the seven-day dosing interval, maintaining steady appetite regulation. Wegovy may help slow gastric emptying, contributing to prolonged satiety after meals and supporting portion control naturally.
Ordering Process: Compare Wegovy and Mounjaro Access
Both Wegovy and Mounjaro follow identical ordering processes through EverydayMeds, ensuring equal access regardless of which treatment your prescriber recommends. The journey begins with a comprehensive 3-minute online clinical assessment covering your medical history, current medications, weight management goals, and any relevant health conditions. Following assessment submission, our qualified prescribers review your information within standard 3 working days, or express 24-hour service for urgent requirements. Once approved, your prescribed treatment ships via next-day delivery using temperature-controlled cold-chain logistics to maintain medication integrity. This streamlined process applies whether you're starting with Wegovy's 0.25mg dose or Mounjaro's initial 2.5mg strength, providing consistent service standards across both treatment options.
Storage Requirements: Wegovy vs Mounjaro Practical Differences
Storage requirements present a key practical difference when you compare Wegovy and Mounjaro for daily life integration. Both treatments require refrigeration at 2-8°C before first use, but Wegovy offers superior room temperature stability, remaining effective for up to 6 weeks below 30°C once removed from refrigeration. Mounjaro provides 21 days of room temperature storage, creating a significant advantage for Wegovy during travel, work situations, or temporary refrigeration unavailability. Both medications use pre-filled injection pens designed for weekly self-administration, though Wegovy's FlexTouch pen system may offer different ergonomics compared to Mounjaro's delivery device. Dose escalation schedules differ substantially, with Wegovy following a 5-stage progression over 16 weeks to reach maintenance dosing, whilst Mounjaro utilises 6 dose levels with its own escalation timeline.
Compare Wegovy and Mounjaro: Individual Suitability Factors
Individual suitability represents perhaps the most crucial factor when you compare Wegovy and Mounjaro for personal weight management strategy. Patient response to GLP-1 monotherapy (Wegovy) versus dual GIP/GLP-1 activation (Mounjaro) can vary significantly based on individual physiology, existing metabolic conditions, and treatment history. Some patients may experience better appetite control with Wegovy's targeted GLP-1 approach, whilst others might benefit from Mounjaro's broader dual receptor activation. Previous experience with similar medications, tolerance to gastrointestinal side effects, and injection frequency preferences all influence treatment selection.
Your prescriber will evaluate factors including BMI, existing comorbidities such as type 2 diabetes or cardiovascular disease, medication interactions, and personal lifestyle requirements. Neither treatment is inherently superior – the optimal choice depends entirely on individual circumstances and clinical judgement. Both Wegovy and Mounjaro are available from EverydayMeds, ensuring your prescriber can select based purely on medical appropriateness rather than availability constraints.
Making Your Decision: Compare Wegovy and Mounjaro Options
Your final decision when comparing Wegovy and Mounjaro should prioritise clinical suitability over cost considerations or convenience factors. Both treatments require long-term commitment, with clinical evidence indicating that weight management benefits depend on continued use alongside lifestyle modifications. EverydayMeds provides equal access to both options through our GPhC-registered pharmacy (#9012878), with identical service standards including clinical assessment, prescriber review, and next-day cold-chain delivery. New customers can use discount code FIRST40, whilst returning customers apply DOSE25 at checkout, ensuring competitive pricing regardless of treatment choice. Start your journey today by completing our clinical assessment at https://everydaymeds.co.uk/collections/weight-loss, where our qualified prescribers will help determine whether Wegovy or Mounjaro aligns better with your individual weight management goals and medical profile.
Reviewed by the EverydayMeds Clinical Team · GPhC #9012878 · Last updated February 2026
